



Australian Government

Department of Health

Office of the Gene Technology Regulator

**Invitation to comment on a clinical trial of a
genetically modified alphavirus for treatment of cancer**

The Gene Technology Regulator is assessing an application from VRT Pharmaceuticals Pty Ltd to conduct a clinical trial of a genetically modified *Getah virus* for treatment of cancer. The trial is proposed to take place at a clinical trial site in Adelaide, South Australia and other locations in Australia as required. Up to 20 trial participants would be treated over a five year period.

The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and welcomes written submissions on issues relating to the protection of human health and safety and the environment prior to making a decision on whether or not to issue the licence. The consultation RARMP and related information can be obtained via the contacts below. Submissions should reference DIR 187 and be received by **7 January 2022**.

Office of the Gene Technology Regulator
MDP 54 GPO Box 9848 CANBERRA ACT 2601
Telephone: 1800 181 030 [OGTR Website](#)
E-mail: ogtr@health.gov.au